Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

ClinicalTrials.gov ID: NCT05952557

Public ClinicalTrials.gov record NCT05952557. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Study identification

NCT ID
NCT05952557
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
5,511 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 5, 2023 (Actual)
Primary completion
Mar 4, 2030 (Estimated)
Completion
May 6, 2037 (Estimated)
Last update posted
Aug 10, 2026

2023 – 2037

United States locations

U.S. sites
111
U.S. states
37
U.S. cities
101
Facility City State ZIP Site status
Research Site Dothan Alabama 36303 —
Research Site Phoenix Arizona 85054 —
Research Site Tucson Arizona 85745 —
Research Site Fayetteville Arkansas 72703 —
Research Site Duarte California 91010 —
Research Site Fountain Valley California 92708 —
Research Site Irvine California 92618 —
Research Site La Jolla California 92093 —
Research Site Los Angeles California 90017 —
Research Site Walnut Creek California 94598 —
Research Site West Hollywood California 90048 —
Research Site Aurora Colorado 80045 —
Research Site Littleton Colorado 80120 —
Research Site Littleton Colorado 80129 —
Research Site New Haven Connecticut 06510 —
Research Site Newark Delaware 19713 —
Research Site Clearwater Florida 33756 —
Research Site Fort Myers Florida 33901 —
Research Site Gainesville Florida 32610 —
Research Site Jacksonville Florida 32224 —
Research Site Pembroke Pines Florida 33028 —
Research Site Plantation Florida 33322 —
Research Site Plantation Florida 33324 —
Research Site St. Petersburg Florida 33705 —
Research Site St. Petersburg Florida 33709 —
Research Site Tallahassee Florida 32308 —
Research Site West Palm Beach Florida 33401 —
Research Site Atlanta Georgia 30318 —
Research Site Marietta Georgia 30060 —
Research Site Thomasville Georgia 31792 —
Research Site Chicago Illinois 60637 —
Research Site Elmhurst Illinois 60126 —
Research Site Naperville Illinois 60540 —
Research Site Urbana Illinois 61801 —
Research Site Fort Wayne Indiana 46804 —
Research Site Des Moines Iowa 50309 —
Research Site Louisville Kentucky 40202 —
Research Site New Orleans Louisiana 70121 —
Research Site Scarborough Maine 04074 —
Research Site Annapolis Maryland 21401 —
Research Site Bethesda Maryland 20817 —
Research Site Towson Maryland 21204 —
Research Site Boston Massachusetts 02111 —
Research Site Boston Massachusetts 02115 —
Research Site Detroit Michigan 48202 —
Research Site Ypsilanti Michigan 48197 —
Research Site Minneapolis Minnesota 55416 —
Research Site Rochester Minnesota 55905 —
Research Site Kansas City Missouri 64111 —
Research Site St Louis Missouri 63110 —
Research Site St Louis Missouri 63131 —
Research Site Lincoln Nebraska 68506 —
Research Site Omaha Nebraska 68124 —
Research Site Hooksett New Hampshire 03106 —
Research Site Manchester New Hampshire 03103 —
Research Site New Brunswick New Jersey 08901 —
Research Site Albuquerque New Mexico 87109 —
Research Site Farmington New Mexico 87401 —
Research Site Bay Shore New York 11706 —
Research Site East Syracuse New York 13057 —
Research Site Greenlawn New York 11740 —
Research Site New Hyde Park New York 11042 —
Research Site New York New York 10029 —
Research Site New York New York 10065 —
Research Site Stony Brook New York 11794 —
Research Site White Plains New York 10601 —
Research Site Charlotte North Carolina 28204 —
Research Site Pinehurst North Carolina 28374 —
Research Site Raleigh North Carolina 27607 —
Research Site Winston-Salem North Carolina 27103 —
Research Site Cincinnati Ohio 45255 —
Research Site Cleveland Ohio 44106 —
Research Site Columbus Ohio 43212 —
Research Site Portland Oregon 97210 —
Research Site Portland Oregon 97213 —
Research Site Portland Oregon 97225 —
Research Site Gettysburg Pennsylvania 17325 —
Research Site Hershey Pennsylvania 17033 —
Research Site Philadelphia Pennsylvania 19104 —
Research Site Pittsburgh Pennsylvania 15213 —
Research Site Sayre Pennsylvania 18840 —
Research Site York Pennsylvania 17403 —
Research Site Charleston South Carolina 29425 —
Research Site Rock Hill South Carolina 29732 —
Research Site Spartanburg South Carolina 29303 —
Research Site Aberdeen South Dakota 57401 —
Research Site Sioux Falls South Dakota 57105 —
Research Site Knoxville Tennessee 37909 —
Research Site Knoxville Tennessee 37920 —
Research Site Memphis Tennessee 38120 —
Research Site Nashville Tennessee 37203 —
Research Site Nashville Tennessee 37232 —
Research Site Austin Texas 78731 —
Research Site Dallas Texas 75246 —
Research Site El Paso Texas 79902 —
Research Site Flower Mound Texas 75028 —
Research Site Houston Texas 77024 —
Research Site San Antonio Texas 78217 —
Research Site Tyler Texas 75702 —
Research Site Charlottesville Virginia 22908 —
Research Site Fairfax Virginia 22031 —
Research Site Midlothian Virginia 23114 —
Research Site Norfolk Virginia 23502 —
Research Site Roanoke Virginia 24014 —
Research Site Winchester Virginia 22601 —
Research Site Puyallup Washington 98373 —
Research Site Spokane Washington 99202 —
Research Site Vancouver Washington 98684 —
Research Site Morgantown West Virginia 26505 —
Research Site Appleton Wisconsin 54911 —
Research Site Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 550 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05952557, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2026 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05952557 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →